

PRECEPTORSHIP PROGRAMME

Lymphoma

Malignant lymphomas
Modern classification and
management of the most
frequent entities

LUGANO
SWITZERLAND

16-17 NOVEMBER 2018

Co-Chairs Martin Dreyling, DE
 Marco Ladetto, IT

ESMO PRECEPTORSHIP PROGRAMME LYMPHOMA

Malignant lymphomas
Modern classification and management of the most frequent entities

Lugano, Switzerland
16-17 November 2018

CO-CHAIRS: Martin Dreyling, Germany
Marco Ladetto, Italy

SPEAKERS: Peter Borchmann, Germany
Andrew Davies, United Kingdom
Martin Hutchings, Denmark
Mats Jerkeman, Sweden
German Ott, Germany
Leticia Quintanilla-Fend, Germany
Emanuele Zucca, Switzerland

LEARNING OBJECTIVES

- To highlight the pathological bases of the most recent lymphoma classification
- To understand the role of PET in staging, re-staging and follow-up
- To review the treatment strategy for the most common lymphoma types
- To dissect the peculiarities of lymphomas arising in particular extranodal sites
- To illustrate special and innovative treatment strategies

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 16 November 2018

08:45-09:00 15'	Opening and welcome	
15'	Welcome from ESMO, objectives and scientific introduction	Marco Ladetto, IT
09:00-10:40 100'	SESSION 1 Pathology and staging	
30'	History of lymphoma classification and the 2016 WHO revision	German Ott, DE
20'	Methods used to diagnose lymphoma	Leticia Quintanilla-Fend, DE
20'	Role of PET in staging and treatment of lymphomas	Martin Hutchings, DK
30'	Participants clinical case discussion (2x15')	Faculty
10:40-11:10	Coffee break	
11:10-12:40 90'	SESSION 2 Indolent	
20'	Pathology of the indolent lymphoid neoplasms	German Ott, DE
20'	MALT	Emanuele Zucca, CH
20'	Treatment of follicular lymphoma	Marco Ladetto, IT
30'	Participants clinical case discussion (2x15')	Faculty
12:40-14:00	Lunch	
14:00-15:30 90'	SESSION 3 Aggressive	
20'	Pathology of aggressive lymphomas	Leticia Quintanilla-Fend, DE
20'	Treatment of DLBCL	Andrew Davies, UK
20'	CNS lymphoma	Martin Dreyling, DE
30'	Participants clinical case discussion (2x15')	Faculty
15:30-16:00	Coffee break	
16:00-17:30 90'	SESSION 4 Other entities	
20'	Management of mantle cell lymphoma	Martin Dreyling, DE
20'	Waldenström	Martin Dreyling, DE
20'	Burkitt, double-hit	Andrew Davies, UK
30'	Participants clinical case discussion (2x15')	Faculty
17:30-18:00 30'	SESSION 5 Q&A session	
19:30	Dinner	

Saturday, 17 November 2018

08:30-10:00 90'	SESSION 6 Hodgkin	
20'	Treatment of first line	Peter Borchmann, DE
20'	Treatment of relapsed disease	Martin Hutchings, DK
20'	Systemic T-Cell	Marco Ladetto, IT
30'	Participants clinical case discussion (2x15')	Faculty
10:00-10:30	Coffee break	
10:30-12:00 90'	SESSION 7 Long term effects and special treatments	
20'	Prevention and screening of long term side effects	Mats Jerkeman, SE
20'	New drugs for lymphoma	Mats Jerkeman, SE
20'	Immune checkpoints and cellular therapies	Peter Borchmann, DE
30'	Participants clinical case discussion (2x15')	Faculty
12:00-12:30 30'	SESSION 8 Q&A session and closing remarks	
12:30-13:30	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion